Musk Is World's First Trillionaire After SpaceX IPO Ivar AI

KQED

SpaceX Blasts Off With a Record-Breaking $75 Billion IPO

BusinessLine

SpaceX IPO pushes Elon Musk’s net worth past $1 trillion

The Times of India

US stocks: SpaceX to make historic listing on Nasdaq on Friday that could make Elon Musk a trillionaire

T3n

Amazon, Nvidia und mehr: Tech-Konzerne pumpen Rekordsumme in deutsches Robotik-Startup

Skift

American Airlines Seeks Widebody Order to Take On Delta and United

Mediaite

NEW: Trump Bombs Iran Second Night In a Row As Negotiations Falter

Metropoles.com

SpaceX, de Elon Musk, faz maior IPO da história e é avaliada em US$ 1,77 trilhão

Biztoc.com

Solar generates more energy than coal in US for 1st time: Report - ABC News

Voachinese.com

SpaceX股票上市首日飙升，马斯克成为全球首位万亿富翁

Crypto Briefing

South Pars Gas Complex petrochemical facility bombed amid escalating Iran conflict

Globo

Ações da SpaceX disparam quase 30% na estreia com procura acima do esperado

Foreign Policy

Trump Says More Strikes on Iran Are Coming

Diariobitcoin.com

Bancos apuestan por combinar stablecoins, depósitos tokenizados y fondos digitales en una sola infraestructura

Xataka.com

China tiene dos ideas para ganar la carrera de la IA: invertir un dineral y dejar a NVIDIA casi sin margen

Crypto Briefing

SpaceX IPO sparks Wall Street frenzy, makes Elon Musk first trillionaire

Crypto Briefing

US officials see 80%-85% chance of peace deal with Iran soon

Yahoo Entertainment

美伊衝突再掀地緣風險美股跌逾1%科技股重挫

Business Insider

SpaceX Live Updates: Elon Musk's Rocket Company Set to Price Hyped IPO

El Mundo

SpaceX capta 75.000 millones en la mayor salida a Bolsa de la historia y sitúa en torno a 1,8 billones el valor de mercado de la empresa

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire